Progressive 11β-Hydroxysteroid Dehydrogenase Type 2 Insufficiency as Kidney Function Declines
The Journal of Clinical Endocrinology & Metabolism · 17.03.2025 · 110 (4) · 1037-1043
DOI: 10.1210/clinem/dgae663 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 23.09.2024. Verfasst von Thomas Uslar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, CETREN-UC, Red Salud UC-CHRISTUS, Pontificia Universidad Católica de Chile, Santiago 8330077, Chile. Hauptthemen laut MEDLINE: 11-beta-Hydroxysteroid Dehydrogenase Type 2, Renal Insufficiency, Chronic, Kidney. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National, NIDDK NIH HHS.
Abstract (Originalsprache)
Background
It has been postulated that chronic kidney disease (CKD) is a state of relative 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) insufficiency, resulting in increased cortisol-mediated mineralocorticoid receptor (MR) activation. We hypothesized that relative 11βHSD2 insufficiency manifests across a wide spectrum of progressively declining kidney function, including within the normal range.
Methods
Adult participants were recruited at 2 academic centers. A discovery cohort (n = 500) enrolled individuals with estimated glomerular filtration rate (eGFR) ranging from normal to CKD stage 5, in whom serum cortisol-to-cortisone (F/E) was measured as a biomarker of 11βHSD2 activity. A validation cohort (n = 101) enrolled only individuals with normal kidney function (eGFR ≥ 60 mL/min/1.73 m2) in whom 11βHSD2 activity was assessed via serum F/E and 11-hydroxy-to-11-keto androgen (11OH/K) ratios following multiple maneuvers: oral sodium suppression test, dexamethasone suppression test (DST), and ACTH-stimulation test (ACTHstim).
Results
In the discovery cohort, lower eGFR was associated with higher F/E (P-trend < .001). Similarly, in the validation cohort, with normal eGFR, an inverse association between eGFR and both F/E and 11OH/K ratios was observed (P-trend < .01), which persisted following DST (P-trend < .001) and ACTHstim (P-trend < .05). The fractional excretion of potassium, a marker of renal MR activity, was higher with higher F/E (P-trend < .01) and with lower eGFR (P-trend < .0001).
Conclusion
A continuum of declining 11βHSD2 activity was observed with progressively lower eGFR in individuals spanning a wide spectrum of kidney function, including those with apparently normal kidney function. These findings implicate cortisol-mediated MR activation in the pathophysiology of hypertension and cardiovascular disease in CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, CETREN-UC, Red Salud UC-CHRISTUS, Pontificia Universidad Católica de Chile, Santiago 8330077, Chile.
- Center for Adrenal Disorders, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Department of Clinical Laboratory, CETREN-UC, Pontificia Universidad Católica de Chile, Santiago 8330077, Chile.
- Division of Endocrinology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
- Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston 02115, USA.
ORCID-Profile: Thomas Uslar, Andrew J Newman, Richard Auchus, René Baudrand, Anand Vaidya
Förderung
- NHLBI NIH HHS
- National
- NIDDK NIH HHS
- Agencia Nacional de Investigación y Desarrollo de Chile
- American Heart Association
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH HHS
- American Heart Association-American Stroke Association
Zitieren
APA
Uslar, T., Newman, A. J., Tapia-Castillo, A., Carvajal, C. A., Fardella, C. E., Allende, F., Solari, S., Tsai, L. C., Milks, J., Cherney, M., Stouffer, D. G., Auchus, R., Brown, J. M., Baudrand, R., & Vaidya, A. (2025). Progressive 11β-Hydroxysteroid Dehydrogenase Type 2 Insufficiency as Kidney Function Declines. The Journal of Clinical Endocrinology & Metabolism, 110(4), 1037-1043. https://doi.org/10.1210/clinem/dgae663
Vancouver
Uslar T, Newman AJ, Tapia-Castillo A, Carvajal CA, Fardella CE, Allende F, et al. Progressive 11β-Hydroxysteroid Dehydrogenase Type 2 Insufficiency as Kidney Function Declines. The Journal of Clinical Endocrinology & Metabolism. 2025;110(4):1037-1043. doi:10.1210/clinem/dgae663
BibTeX
@article{Uslar2025,
author = {Uslar, Thomas and Newman, Andrew J and Tapia-Castillo, Alejandra and Carvajal, Cristian A and Fardella, Carlos E and Allende, Fidel and Solari, Sandra and Tsai, Laura C and Milks, Julia and Cherney, Michael and Stouffer, David G and Auchus, Richard and Brown, Jenifer M and Baudrand, René and Vaidya, Anand},
title = {Progressive 11β-Hydroxysteroid Dehydrogenase Type 2 Insufficiency as Kidney Function Declines},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {4},
pages = {1037--1043},
doi = {10.1210/clinem/dgae663}
}
EUVIMED